EASL Updates: Intercept Says Biomarker Data Bolster OCA’s Case For Fibrosis Benefit

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Intercept and Axcella provide updated data on their NASH programs at the International Liver Conference, while CymaBay offers the full dataset for seladelpar in PBC.

DATA_Puzzle Piece_186976547_1200.jpg
Companies presented new data in NASH and PBC at EASL 2020

The European Association for the Study of the Liver’s virtual International Liver Conference kicked off with largely incremental data in therapy areas like non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Among the highlights, Intercept Pharmaceuticals, Inc. reported on 27 August that biomarker data from its Phase III REGENERATE study of obeticholic acid (OCA) in NASH provides further evidence that the drug can provide patients with an improvement in fibrosis, Axcella Health, Inc. presented data on its NASH candidate’s benefits on metabolism, inflammation and fibrosis, and CymaBay Therapeutics, Inc. unveiled final Phase II data for seladelpar in PBC.

Coming off a 29 June complete response letter from the US Food and Drug Administration, Intercept is preparing for a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D